Alessandra Raimondi, Young Woo Kim, Won Ki Kang, Ruth E Langley, Yoon Young Choi, Kyoung-Mee Kim, Matthew Guy Nankivell, Giovanni Randon, Myeong-Cherl Kook, Ji Yeong An, Heike I Grabsch, Michele Prisciandaro, Federico Nichetti, Sung Hoon Noh, Tae Sung Sohn, Sung Kim, Andrew Wotherspoon, Federica Morano, David Cunningham, Jeeyun Lee, Jae-Ho Cheong, Elizabeth Catherine Smyth, Filippo Pietrantonio
BACKGROUND: Surgery plus peri-operative/adjuvant chemotherapy is the standard of care for locally advanced GC/GEJC, though with unsatisfactory results. dMMR/MSI-high tumors have better prognosis and scant benefit from chemotherapy as compared to pMMR/MSS ones. The differential outcome of therapies in terms of safety and efficacy according to sex is still debated in GC/GEJC patients. METHODS: We previously performed an individual patient data pooled analysis of MAGIC, CLASSIC, ITACA-S, and ARTIST trials including GC/GEJC patients treated with surgery alone or surgery plus peri-operative/adjuvant chemotherapy to assess the value of MSI status...
April 4, 2024: European Journal of Cancer